Article
Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Clinical colorectal cancer - 1 Mar 2021
Lenz Heinz-Josef, Argiles Guillem, Yoshino Takayuki, Tejpar Sabine, Ciardiello Fortunato, Braunger Jürgen, Salnikov Alexey V, Gabrielyan Ogsen, Schmid Ramona, Höfler Josef, Kitzing Thomas, Van Cutsem Eric
Abstract excerpt
INTRODUCTION: LUME-Colon 1 (NCT02149108) was a global, placebo-controlled phase III study of nintedanib in advanced colorectal cancer (CRC). Pre-specified biomarker analyses investigated the association of CRC consensus molecular subtypes (CMS) and tumor genomic and circulating biomarkers with clinical outcomes. MATERIALS AND METHODS: Archival tumor tissue, cell-free DNA (cfDNA), and plasma samples were collected...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.